Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 28, 2023

Tumor-Agnostic ctDNA Levels by mFAST-SeqS in Patients With HR+/HER2− MBC as a Biomarker for Survival

NPJ breast cancer


Additional Info

NPJ breast cancer
Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival
NPJ Breast Cancer 2023 Jul 14;9(1)61, N Verschoor, V de Weerd, MN Van, J Kraan, M Smid, JB Heijns, JC Drooger, JM Zuetenhorst, A van der Padt-Pruijsten, A Jager, S Sleijfer, JWM Martens, SM Wilting

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading